ABBV250103C177500
- 3.72
- +1.68+82.35%
AbbVie Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Santa Claus Came Without Rallying the Troops | Live Stock
AbbVie Hits 4-week High
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com
AbbVie (ABBV) Gains As Market Dips: What You Should Know
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Is AbbVie Inc. (ABBV) the Best Dividend Growth Stock to Buy and Hold in 2025?
Weekly Buzz: So far, Santa is Letting us Down
AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook